Nice D&B Co., Ltd. (KOSDAQ:130580)
5,930.00
-140.00 (-2.31%)
At close: Feb 26, 2026
Nice D&B Revenue
Nice D&B had revenue of 22.37B KRW in the quarter ending September 30, 2025, with 7.99% growth. This brings the company's revenue in the last twelve months to 92.11B, up 5.42% year-over-year. In the year 2024, Nice D&B had annual revenue of 89.66B with 1.99% growth.
Revenue (ttm)
92.11B
Revenue Growth
+5.42%
P/S Ratio
0.98
Revenue / Employee
495.21M
Employees
186
Market Cap
90.55B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 89.66B | 1.75B | 1.99% |
| Dec 31, 2023 | 87.91B | -4.28B | -4.64% |
| Dec 31, 2022 | 92.19B | 3.51B | 3.95% |
| Dec 31, 2021 | 88.68B | 6.49B | 7.89% |
| Dec 31, 2020 | 82.20B | 4.87B | 6.29% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Woowon Development | 379.63B |
| Inics | 123.55B |
| Hwail Pharmaceutical | 107.87B |
| FOCUS AI | 51.57B |
| Choong Ang Vaccine Laboratory | 39.19B |
| Humasis | 35.60B |
| Raphas | 32.16B |
| Korea Cable T.V Chung-Buk System | 18.31B |